Blood lipid control in patients with peripheral arterial disease (PAD) continues to be “suboptimal,” researchers on a new study conclude. The observational analysis showed that despite their increased risk for cardiovascular and limb events, lipid-lowering therapy (LLT) was generally underused in patients with PAD, and many who were treated still had elevated low-density lipoprotein cholesterol